



Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Community
Ask the community for help and clear up your study doubts
Discover the best universities in your country according to Docsity users
Free resources
Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors
The pharmaceutical care model is now defined as a patient-centered way to deliver medication manage- ment services. The model stresses.
Typology: Study notes
1 / 5
This page cannot be seen from the preview
Don't miss anything!
Practice Model Description of Model Key Elements Steps
Pharmaceutical care 1
The pharmaceutical care model is now defined as a patient-centered way to deliver medication manage- ment services. The model stresses a pharmacist’s responsibility for a patient’s drug-related needs and being held accountable for the com- mitment. The purpose is to achieve positive patient outcomes. The phar- macist ensures that all of a patient’s drug therapy is indicated, effective, and safe and that the patient is able and willing to adhere to instructions. It is a generalist practice, consistent with the concepts of primary care and the medical home.
The pharmaceutical care model has three key com- ponents:
The pharmaceutical care process has three key steps:
In the standards of care for pharmaceutical care, the practitioner:
1) ASSESSMENT of patient’s drug-related needs Includes a pharmacotherapy workup and a full review of systems to identify DTPs. All DTPs are categorized and must fall under one of four categories, composed of seven types of DTPs: a. Indication i. Unnecessary drug therapy ii. Needs additional drug therapy b. Effectiveness i. Ineffective drug ii. Dosage too low c. Safety i. Adverse drug reaction ii. Dosage too high d. Adherence i. Patient not able or willing to take medication 2) CARE PLAN development to meet patient’s needs Four categories of interventions are selected to establish goals of therapy: a. Resolve DTPs. b. Achieve goals of therapy. c. Prevent future DTPs. d. Schedule follow-up. Types of interventions that can occur: a. Initiate new drug therapy. b. Change dosage regimen. c. Change the drug product. d. Discontinue drug therapy. e. Institute a monitoring plan. f. Patient-specific instructions g. Removal of barriers to obtain medication h. Drug administration device provided i. Refer patient. 3) Follow-up EVALUATION Each condition is categorized into eight predetermined outcomes: a. Resolved b. Stable c. Improved d. Partly improved e. Unimproved f. Worsened g. Failure h. Expired (patient died)
Practice Model Description of Model Key Elements Steps
Medication therapy management
(MTM) 2
MTM is defined as a distinct service or group of services that optimize therapeutic outcomes for individual patients. In this model, the patient is empowered to take an ac- tive role in managing his or her medications.
All MTM services should include: (1) Establishing a pharmacist-patient relationship in which the pharmacist provides individualized services specific to the patient (or caregiver) to whom services are provided (2) The interaction between the patient (or caregiver) and pharmacist preferably occurs through face-to- face communication. (3) Opportunities for pharmacists and other quali- fied health care providers to identify patients who should receive MTM services (4) Payment for MTM services consistent with con- temporary provider payment rates (5) Processes to improve continuity of care, out- comes, and outcome measures
The MTM service model has five core elements: 1) Medication therapy review (MTR) A systematic process of collecting patient-specific information a. Assessing medications to identify medication-related problems (MRPs) by reviewing indication, effectiveness, safety, and adherence b. Developing a prioritized list of MRPs c. Creating a plan to resolve MRPs Two main types of MTR: a. Comprehensive: annual and after transitions of care b. Targeted: addresses specific MRP 2) Personal medication record (PMR) a. A comprehensive record of all medications (prescription, over-the-counter, herbal, and other dietary supplements), which is intended for patients to use in medication self-management b. Can be created as part of discharge process in the institutional setting or as part of patient care in the ambulatory care setting c. Patients are responsible for documenting any changes to their therapeutic regimens to ensure a current and accurate record. 3) Medication-related action plan (MAP) a. Intended for patient use; contains a list of actions for self-management The pharmacist-created MAP includes items the patient can act on that are within the pharmacist’s scope of practice or agreed on by other mem- bers of the health care team. 4) Intervention and/or referral Recommendations on selection of medications; options to address MRPs, recom- mended monitoring parameters, and follow-up care 5) Documentation and follow-up a. MTM services should be documented in a consistent manner, and follow-up MTM visits are scheduled on the basis of the individual patient’s medication-related needs. b. Documentation for patients may include the PMR, MAP, and educational materials. c. Documentation to physicians may include a cover letter, the patient’s PMR, the SOAP note, and the care plan.
Practice Model Description of Model Key Elements Steps
SHPA
(Society of Hospital Pharmacists of Australia) 4
The SHPA developed Standards of Practice for clinical pharmacy with the objective to “optimize patient outcomes by work- ing to achieve the quality use of medicines (QUM).” Clinical pharmacy practice is defined as “the practice of pharmacy as part of a multidisciplinary health care team directed at achieving QUM.”
The document includes not only a model of practice, but also the other types of activities clinical pharmacists may be engaged in, including rounding, providing drug information to health pro- fessionals and patients, reporting and managing adverse drug reactions, and participating in research.
The standards define the procedures for clinical phar- macy services for individual patients in great detail. In these standards, the two overlapping components are (1) a MAP and (2) the discrete clinical activities that contribute to the plan.
The MAP focuses on overall patient outcomes, and it states that to carry out the plan, a pharmacist will perform several specific clinical activities. The MAP contains six fundamental components:
a. Interpretation of patient-specific data b. Identification of clinical problems (focus on prob- lems that require their expertise) c. Establishment of therapeutic goals d. Evaluation of therapeutic options e. Individualization of therapy f. Monitoring of patient outcomes
10 specific clinical activities that contribute to the components of a MAP:
For each of the above clinical activities, an appendix is provided. Each activity description then has an introduction section, goals for the activity, procedures for the activity (extensive), and a role for a pharmacy technician with the activity (if applicable).
The standards also provide guidance on documenting clinical activities and the MAP.
Practice Model Description of Model Key Elements Steps
iMAP program
(individualized medication assess- ment and planning) (Mary Roth, per- sonal communica- tion, May 2012)
The iMAP program is a patient- centered, comprehensive MTM program. The program consists of 10 essential steps in the provision of patient care. Although it is being studied in those 65 years and older, it is applicable to other age groups, especially patients with multiple comorbidities and using multiple medications.
A full description of this model is not available at this time.
The iMAP program is outlined in 10 essential steps. Care along each step is individualized to meet the needs of the patient. Several steps of the process are further described, including conducting a compre- hensive medication review, identifying MRPs, and documenting encounters.
For example, when assessing and documenting MRPs, the clinical pharmacist is guided by the iMAP tool (REF #5). This tool categorizes MRPs into seven general categories. Several subcategories under each large category are provided to further classify the MRP. The general categories are:
Once an MRP is identified and documented, a recom- mendation or intervention is proposed to the primary care provider, consensus is reached, and the plan is implemented to optimize medication use. To track interventions made by the clinical pharmacist, a list of 20 possible recommendations is included as part of the iMAP tool to document the intervention used to resolve the MRP (e.g., add a drug, discontinue a drug, decrease a dose, increase a dose, switch to a more effective agent).
The 10 steps in this MTM model: